Ocugen’s Strategic Push: Can the Biotech Firm Deliver on Its Ambitious Timeline?
03.10.2025 - 08:54:04 | boerse-global.de
Ocugen is executing a strategic campaign to position itself at the forefront of gene therapy. The company has announced a packed schedule for October, with presentations planned for three major industry conferences. This visibility push is a core component of a clearly defined corporate objective: to submit three regulatory applications by the year 2028.
The company’s leadership team is set for a high-profile month, beginning with the “Cell & Gene Meeting on the Mesa” in Phoenix on October 6. There, Executive Vice President Abhi Gupta will represent Ocugen. The focus then shifts to New York for two additional events. CEO Dr. Shankar Musunuri is scheduled to speak at Chardan’s 9th Genetic Medicines Conference on October 21, followed by a presentation the very... Read more...
So schätzen die Börsenprofis Ocugen’s Aktien ein!
Für. Immer. Kostenlos.
